Amylyx Q2 FY26 net loss widens to $43.4 million; SG&A expenses climb to $21.9 million

Reuters2026/08/06 11:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amylyx posted a Q2 net loss of USD 43.4 million, or USD 0.39 a share, versus a net loss of USD 41.4 million, or USD 0.46 a year earlier.
R&D expenses fell 12.5% to USD 23.8 million, driven by lower spending on AMX0035 in progressive supranuclear palsy.
SG&A expenses rose 40.4% to USD 21.9 million on higher legal costs and increased investment in commercial strategic initiatives.
Cash, cash equivalents, and short-term investments slipped to USD 250.8 million; cash runway is expected to fund operations into 2028.
Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia is due to report topline data in late August or early September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amylyx Q2 FY26 net loss widens to $43.4 million; SG&A expenses climb to $21.9 million

You may also like

Crypto prices